Entera Bio Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.62
- Today's High:
- $0.7399
- Open Price:
- $0.7
- 52W Low:
- $0.472
- 52W High:
- $2.12
- Prev. Close:
- $0.669
- Volume:
- 363672
Company Statistics
- Market Cap.:
- $25.59 million
- Book Value:
- 0.35
- Revenue TTM:
- $66000
- Operating Margin TTM:
- -17956.06%
- Gross Profit TTM:
- $33000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -43.68%
- Return on Equity TTM:
- -76.96%
Company Profile
Entera Bio Ltd had its IPO on 2018-06-28 under the ticker symbol ENTX.
The company operates in the Healthcare sector and Biotechnology industry. Entera Bio Ltd has a staff strength of 18 employees.
Stock update
Shares of Entera Bio Ltd opened at $0.7 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.62 - $0.74, and closed at $0.66.
This is a -1.33% slip from the previous day's closing price.
A total volume of 363,672 shares were traded at the close of the day’s session.
In the last one week, shares of Entera Bio Ltd have slipped by -1.77%.
Entera Bio Ltd's Key Ratios
Entera Bio Ltd has a market cap of $25.59 million, indicating a price to book ratio of 1.2615 and a price to sales ratio of 63.3717.
In the last 12-months Entera Bio Ltd’s revenue was $66000 with a gross profit of $33000 and an EBITDA of $-11789000. The EBITDA ratio measures Entera Bio Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Entera Bio Ltd’s operating margin was -17956.06% while its return on assets stood at -43.68% with a return of equity of -76.96%.
In Q1, Entera Bio Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 91.5%.
Entera Bio Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.46 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Entera Bio Ltd’s profitability.
Entera Bio Ltd stock is trading at a EV to sales ratio of 13.5585 and a EV to EBITDA ratio of -0.2765. Its price to sales ratio in the trailing 12-months stood at 63.3717.
Entera Bio Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $11.61 million
- Total Liabilities
- $1.49 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $11000
- Dividend Payout Ratio
- 0%
Entera Bio Ltd ended 2024 with $11.61 million in total assets and $0 in total liabilities. Its intangible assets were valued at $11.61 million while shareholder equity stood at $10.08 million.
Entera Bio Ltd ended 2024 with $0 in deferred long-term liabilities, $1.49 million in other current liabilities, in common stock, $-97687000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.69 million and cash and short-term investments were $10.69 million. The company’s total short-term debt was $48,000 while long-term debt stood at $0.
Entera Bio Ltd’s total current assets stands at $11.37 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $682000.00 compared to accounts payable of $1.49 million and inventory worth $0.
In 2024, Entera Bio Ltd's operating cash flow was $0 while its capital expenditure stood at $11000.
Comparatively, Entera Bio Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.66
- 52-Week High
- $2.12
- 52-Week Low
- $0.472
- Analyst Target Price
- $5.67
Entera Bio Ltd stock is currently trading at $0.66 per share. It touched a 52-week high of $2.12 and a 52-week low of $2.12. Analysts tracking the stock have a 12-month average target price of $5.67.
Its 50-day moving average was $0.75 and 200-day moving average was $0.85 The short ratio stood at 0.88 indicating a short percent outstanding of 0%.
Around 2304.5% of the company’s stock are held by insiders while 1063.3% are held by institutions.
Frequently Asked Questions About Entera Bio Ltd
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company’s lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.